ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 126

Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in African-American Patients: Disease Associations and Clinical Outcomes in an Urban Cohort

Philip McCarthy1, Jenna Hudy2, Marie Melville2, Danielle Robson1, John McKinnon2, Sandeep Soman2 and Kathleen Maksimowicz-McKinnon3, 1Michigan State University College of Osteopathic Medicine, East Lansing, MI, 2Henry Ford Hospital, Detroit, MI, 3Rheumatology, Henry Ford Hospital, Detroit, MI

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: African-Americans, ANCA, outcomes and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Healthcare Disparities in Rheumatology - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African-American populations. The significance of and associations with ANCA in African-Americans, especially outside of AAV, has not been well characterized.

Methods: Retrospective chart review of patients self-identified as African-American with positive ANCA testing was performed. Records were reviewed in detail to classify patients as definite AAV using the revised Chapel Hill 2012 AAV criteria, probable AAV (in patients in whom biopsy evidence was absent but with a preponderance of clinical and serologic evidence to support the diagnosis), possible AAV (no biopsy evidence, compatible clinical/serologic picture, but less compelling evidence), and unlikely AAV. The presence of other autoimmune disorders, infectious disorders, and medications known to be associated with ANCA positivity were also documented.

Results: 77 African-American patients with ANCA were identified, of which 49 (63.6%) were female with a mean age of 57 at symptom onset. Of these patients, 21 had established AAV (27.3%), 3 had probable AAV (3.9%), 14 had possible AAV (18.2%) and 10 (13%) were deemed unlikely to have AAV. Eleven patients (14.3%) had drug-induced vasculitis, either from hydralazine or cocaine use. Sixteen patients (20.8%) had other autoimmune diseases, and of these, half were determined to have active vasculitis. Only 2 patients (2.6%) had vasculitis secondary to chronic viral infection (hepatitis). Patients most often were P-ANCA positive (51.9%), and often had other positive autoimmune serologies including antinuclear antibodies (42.9%) and rheumatoid factor (18.2%). Remarkably, 30 patients (38.9%) developed end-stage renal disease (ESRD). Considering other common comorbidities in this population potentially related to renal failure, diabetes mellitus (DM) was present in 20.7% of patients (mean duration=2 years, mean glycated hemoglobin=6.2) and hypertension (HTN) in 76.6% (mean duration 8 years, mean number of medications=1). Fourteen patients (18.1%) died, with a mean time to death of only 10 months from the time of their underlying diagnosis associated with ANCA.

Conclusion: ANCA are often detected in conditions other than AAV in African-American patients, and are frequently associated with other etiologies of vasculitis. Over one-third of African-American patients with ANCA developed ESRD, which given the data regarding HTN and DM in this population, seems unlikely to be wholly attributable to these comorbidities alone. Further study to explore the potential pathogenic role of ANCA in African-American patients, especially in regard to renal disease, is warranted.


Disclosure: P. McCarthy, None; J. Hudy, None; M. Melville, None; D. Robson, None; J. McKinnon, None; S. Soman, None; K. Maksimowicz-McKinnon, None.

To cite this abstract in AMA style:

McCarthy P, Hudy J, Melville M, Robson D, McKinnon J, Soman S, Maksimowicz-McKinnon K. Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in African-American Patients: Disease Associations and Clinical Outcomes in an Urban Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/anti-neutrophil-cytoplasmic-antibodies-anca-in-african-american-patients-disease-associations-and-clinical-outcomes-in-an-urban-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-neutrophil-cytoplasmic-antibodies-anca-in-african-american-patients-disease-associations-and-clinical-outcomes-in-an-urban-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology